Leukemia, Chronic Lymphocytic 2 disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

DBM MCID: LKM056 MIFTS: 52	Leukemia, Chronic Lymphocytic 2 (DBM) Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Leukemia, Chronic Lymphocytic 2

MalaCards integrated aliases for Leukemia, Chronic Lymphocytic 2:

Name: Leukemia, Chronic Lymphocytic 2 ⁵⁷

Leukemia, Chronic Lymphocytic, Susceptibility to, 2 ⁵⁷ ²⁸ ¹²

B-Cell Malignancy, Low-Grade ⁵⁷ ⁷¹

Leukemia, Chronic Lymphocytic, B-Cell ⁵⁷

Lymphocytic Leukemia Chronic B-Cell ⁵³

Disrupted in B-Cell Malignancy ⁵⁷

Chronic Lymphocytic Leukaemia ³³

Chronic Lymphocytic Leukemia ⁷¹

Chronic Lymphatic Leukaemia ³³

Lymphoplasmacytic Leukaemia ³³

Chronic Lymphoid Leukaemia ³³

Chronic Lymph Leukaemia ³³

Clls2 ⁵⁷

Bcll ⁵⁷

Dbm ⁵⁷

Characteristics:

Inheritance:

Autosomal dominant ⁵⁷

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases
Anatomical: Immune diseases Blood diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Neoplasms

Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue

Lymphoid leukaemia

Chronic lymphocytic leukaemia of B-cell type

ICD11: ³³

Neoplasms

Neoplasms of haematopoietic or lymphoid tissues

Mature B-cell neoplasms

Mature B-cell neoplasm with leukaemic behaviour

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Chronic lymphocytic leukaemia of B-cell type

External Ids:

OMIM® ⁵⁷ 109543

ICD10 ³¹ C91.1

MedGen ⁴⁰ C1868683

SNOMED-CT via HPO ⁶⁹ 277473004 51092000 92814006

ICD11 ³³ 1726842351

UMLS ⁷¹ C0023434 C1868683

Sources

Summaries for Leukemia, Chronic Lymphocytic 2

MalaCards based summary: Leukemia, Chronic Lymphocytic 2, also known as leukemia, chronic lymphocytic, susceptibility to, 2, is related to chronic lymphocytic leukemia/small lymphocytic lymphoma and b-cell non-hodgkin lymphoma, and has symptoms including fatigue, angina pectoris and chest pain. An important gene associated with Leukemia, Chronic Lymphocytic 2 is CLLS2 (Disrupted In B-Cell Neoplasia), and among its related pathways/superpathways are Hematopoietic Stem Cells and Lineage-specific Markers and Interleukin-4 and Interleukin-13 signaling. The drugs Valganciclovir and Rituximab have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone marrow and b cells, and related phenotypes are chronic lymphatic leukemia and immune system

More information from OMIM: 109543

Sources

Related Diseases for Leukemia, Chronic Lymphocytic 2

Diseases in the Leukemia, Chronic Lymphocytic family:

Leukemia, Chronic Lymphocytic 2	Leukemia, Chronic Lymphocytic 1
Leukemia, Chronic Lymphocytic 3	Leukemia, Chronic Lymphocytic 4
Leukemia, Chronic Lymphocytic 5	Adult Acute Lymphocytic Leukemia

Diseases related to Leukemia, Chronic Lymphocytic 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 554)

#	Related Disease	Score	Top Affiliating Genes
1	chronic lymphocytic leukemia/small lymphocytic lymphoma	31.6	ZAP70 CD5 CD38 BCL2
2	b-cell non-hodgkin lymphoma	30.5	MS4A1 ATM
3	chromosome 13q14 deletion syndrome	30.5	ZAP70 CD5 CD38 ATM
4	burkitt lymphoma	30.2	MS4A1 FCER2 BCL2 ATM
5	marginal zone b-cell lymphoma	30.1	CD5 CD38 BCL2
6	lymphoma, mucosa-associated lymphoid type	30.1	ZAP70 CD5 BCL2
7	chromosomal triplication	30.1	ZAP70 BCL3
8	anemia, autoimmune hemolytic	30.0	ZAP70 CD5 CD38
9	prolymphocytic leukemia	29.9	ZAP70 MS4A1 FCER2 CD5 CD38 ATM
10	t-cell prolymphocytic leukemia	29.9	CD5 ATM
11	leukemia, acute lymphoblastic	29.9	ZAP70 MCL1 CD5 CD38 BCL2
12	lymphoplasmacytic lymphoma	29.8	CD5 CD38 BCL2
13	mantle cell lymphoma	29.8	ZAP70 MCL1 CD5 CD38 BCL2 ATM
14	bone lymphoma	29.8	CD5 BCL2
15	b-cell expansion with nfkb and t-cell anergy	29.8	ZAP70 MS4A1 FCER2 CD5 CD38
16	composite lymphoma	29.7	CD5 BCL2
17	plasmacytoma	29.6	CD5 CD38 BCL2
18	waldenstroem's macroglobulinemia	29.5	ZAP70 MS4A1 IGHM CD5 CD38
19	follicular lymphoma	29.4	MS4A1 MCL1 IGHM FCER2 CD5 BCL2
20	anaplastic large cell lymphoma	29.3	MCL1 BCL3 BCL2
21	mature b-cell neoplasm	29.3	MCL1 CD5 CD38 BCL2
22	richter's syndrome	29.2	ZAP70 CD5 CD38 BCL2 ATM
23	myeloma, multiple	29.0	MCL1 CD38 BCL2 ATM
24	immune deficiency disease	28.9	ZAP70 MS4A1 CD5 CD38 ATM
25	leukemia, acute myeloid	28.9	MCL1 CD5 CD38 BCL2 ATM
26	leukemia	28.5	ZAP70 MCL1 CD38 BCL3 BCL2 ATM
27	lymphoma, hodgkin, classic	28.3	ZAP70 MS4A1 MCL1 BCL3 BCL2 ATM
28	lymphoma, non-hodgkin, familial	28.0	MS4A1 MCL1 FCER2 CD5 CD38 BCL3
29	lymphoma	27.9	MS4A1 MCL1 CD5 CD38 BCL3 BCL2
30	b-cell lymphoma	27.8	ZAP70 MS4A1 MCL1 FCER2 CD5 BCL3
31	leukemia, chronic lymphocytic	26.8	ZAP70 MS4A1 MCL1 IGHM FCER2 CLLS2
32	neutropenia	10.9
33	thrombocytopenia	10.7
34	chromosome 17p deletion	10.7
35	b-cell prolymphocytic leukemia	10.7
36	diarrhea	10.6
37	factor vii deficiency	10.6
38	kidney disease	10.5
39	jacobsen syndrome	10.5
40	myelodysplastic syndrome	10.5
41	glomerulonephritis	10.5
42	telangiectasis	10.5
43	ataxia-telangiectasia	10.4
44	aplastic anemia	10.4
45	pancytopenia	10.4
46	graft-versus-host disease	10.4
47	tatton-brown-rahman syndrome	10.4
48	acute kidney failure	10.4
49	exanthem	10.4
50	skin squamous cell carcinoma	10.4

Graphical network of the top 20 diseases related to Leukemia, Chronic Lymphocytic 2:

Sources

Symptoms & Phenotypes for Leukemia, Chronic Lymphocytic 2

Human phenotypes related to Leukemia, Chronic Lymphocytic 2:

³⁰

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	chronic lymphatic leukemia ³⁰			HP:0005550

Symptoms via clinical synopsis from OMIM®:

⁵⁷ (Updated 08-Dec-2022)

Oncology:
b-cell chronic lymphocytic leukemia (cll)

Clinical features from OMIM®:

109543 (Updated 08-Dec-2022)

UMLS symptoms related to Leukemia, Chronic Lymphocytic 2:

fatigue; angina pectoris; chest pain; edema

MGI Mouse Phenotypes related to Leukemia, Chronic Lymphocytic 2:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	immune system	MP:0005387	9.65	ATM BCL2 BCL3 CD38 CD5 FCER2
2	hematopoietic system	MP:0005397	9.32	ATM BCL2 BCL3 CD38 CD5 FCER2

Sources

Drugs & Therapeutics for Leukemia, Chronic Lymphocytic 2

Drugs for Leukemia, Chronic Lymphocytic 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 422)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Valganciclovir

Approved, Investigational

Phase 4

175865-60-8

64147

Rituximab

Approved

Phase 4

174722-31-7

Chlorambucil

Approved

Phase 4

305-03-3

2708

Heptavalent Pneumococcal Conjugate Vaccine

Phase 4

Antineoplastic Agents, Immunological

Phase 4

Epoetin Alfa

Phase 4

Hematinics

Phase 4

Chrysarobin

Phase 4

Cladribine

Approved, Investigational

Phase 3

4291-63-8

20279

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 3

1177-87-3

3680

Dexamethasone

Approved, Investigational, Vet_approved

Phase 3

50-02-2

3003 5743

Miconazole

Approved, Investigational, Vet_approved

Phase 3

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 3

23593-75-1

2812

Iron

Approved

Phase 3

7439-89-6

29936

Darbepoetin alfa

Approved, Investigational

Phase 3

209810-58-2

Cisplatin

Approved

Phase 3

15663-27-1

2767 5702198 441203

Acalabrutinib

Approved, Investigational

Phase 3

1420477-60-6

71226663 71226662

Fludarabine

Approved

Phase 3

75607-67-9, 21679-14-1

30751 657237

Cyclophosphamide

Approved, Investigational

Phase 3

50-18-0, 6055-19-2

2907

Vidarabine

Approved, Investigational

Phase 3

24356-66-9

21704

Levoleucovorin

Approved, Experimental, Investigational

Phase 3

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Triamcinolone

Approved, Vet_approved

Phase 3

124-94-7

31307

Pancrelipase

Approved, Investigational

Phase 3

53608-75-6

8519

Lenograstim

Approved, Investigational

Phase 3

135968-09-1

Mitoxantrone

Approved, Investigational

Phase 3

70476-82-3, 65271-80-9

4212

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 3

59-30-3

6037

Tenofovir

Experimental, Investigational

Phase 3

147127-20-6, 202138-50-9

464205 6398764

Reverse Transcriptase Inhibitors

Phase 3

Cyclosporins

Phase 3

Antifungal Agents

Phase 3

Ferric Oxide, Saccharated

Phase 3

Antirheumatic Agents

Phase 3

Alkylating Agents

Phase 3

Antineoplastic Agents, Alkylating

Phase 3

Immunosuppressive Agents

Phase 3

Immunologic Factors

Phase 3

Antimetabolites

Phase 3

Anti-Infective Agents

Phase 3

Antiviral Agents

Phase 3

Folic Acid Antagonists

Phase 3

Folate

Phase 3

Vitamin B9

Phase 3

Vitamin B Complex

Phase 3

Caseins

Phase 2, Phase 3

Triamcinolone hexacetonide

Phase 3

Triamcinolone diacetate

Phase 3

Triamcinolone Acetonide

Phase 3

6436

Immunoglobulin G

Phase 3

Liver Extracts

Phase 3

Paraproteins

Phase 3

Interventional clinical trials:

(show top 50) (show all 1243)

#	Name	Status	NCT ID	Phase	Drugs
1	A Multicenter, Open-Label Study of Nipent, Cytoxan and Rituxan in Patients With Previously Untreated or Treated Chronic Lymphocytic Leukemia.	Unknown status	NCT00131313	Phase 4	Nipent, Cytoxan, Rituxan
2	The Effects of PROCRIT (Epoetin Alfa) on Hemoglobin, Symptom Distress, and Quality of Life During Chemotherapy in Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma Patients With Mild to Moderate Anemia	Completed	NCT00524407	Phase 4	Epoetin alfa
3	A Multicenter Study to Confirm the Efficacy and Safety of Fludara i.v. (Fludarabine Phosphate, SH L 573), Administered in 6 Treatment Cycles (1 Treatment Cycle: 5-consecutive Day Dosing, Followed by an Observation Period of 23 Days) in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia	Completed	NCT00220311	Phase 4	Fludarabine Phosphate (Fludara)
4	A Randomized Study to Assess the Effect on Response Rate of MabThera (Rituximab) Added to a Standard Chemotherapy, Bendamustine or Chlorambucil, in Patients With Chronic Lymphocytic Leukemia	Completed	NCT01056510	Phase 4	bendamustine;chlorambucil;rituximab [MabThera/Rituxan]
5	Treatment of Chronic Lymphocytic Leukemia With the Use of an Antiviral Compound - a Proof of Principle Study	Completed	NCT01255644	Phase 4	Valganciclovir
6	The Duration of Humoral Immunity and the Memory Cell Function After Vaccination With 7-valent Pneumococcal Conjugate Vaccine in CLL	Completed	NCT00919321	Phase 4
7	A Prospective, Multi-centre, Phase IV Clinical Trial to Assess the Safety and Efficacy of Acalabrutinib Capsules in Indian Adult Patients With Chronic Lymphocytic Leukaemia and Relapsed and Refractory Mantle Cell Lymphoma	Active, not recruiting	NCT04930536	Phase 4	Acalabrutinib capsule
8	A Prospective, Multicenter, Open Label Single Arm Phase IV Clinical Trial to Assess Safety of ImbruvicaTM (Ibrutinib Capsules 140 mg) in Indian Patients With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion	Active, not recruiting	NCT03190330	Phase 4	Ibrutinib 420 mg;Ibrutinib 560 mg
9	Long Term Effect on Immune Response After Pneumococcal Vaccination in Patients With Chronic Lymphocytic Leukemia and Evaluation of the Effect of Revaccination	Active, not recruiting	NCT05316831	Phase 4
10	Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens	Not yet recruiting	NCT04790045	Phase 4	Venetoclax
11	Open Multicentric Study to Assess the Hematopoyetic Response in Terms of Increase of Hemoglobin Levels of Patients With Anemia Related to Non- Hodgkin Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma, Treated With Erythropoietin B (Recormon) Using Pre-filled Syringe With 30000 IU, as Well as to Quantify the Risk Factors of Anemia and Its Impact on Quality of Life Related to Treatment	Terminated	NCT02608060	Phase 4	Epoetin Beta
12	Prospective Randomized Study to Compare Efficacy and Safety of RFC-Lite (Rituximab, Fludarabine, Cyclophosphamide) Regimen With LR (Rituximab, Chlorambucil) as a First-Line Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia and Unfavorable Somatic Status	Terminated	NCT01283386	Phase 4	Chlorambucil;Cyclophosphamide;Fludarabine;Rituximab
13	Prospective Study of Efficacy and Safety of RFC (Rituximab, Fludarabine, Cyclophosphamide) Regimen as a First-Line Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia and Favorable Somatic Status	Terminated	NCT01271010	Phase 4	Cyclophosphamide;Fludarabine;Rituximab
14	A Randomised Investigation of Alternative Ofatumumab-containing Regimens in Less Fit Patients With CLL	Unknown status	NCT01678430	Phase 3	Ofatumumab;Chlorambucil;Bendamustine
15	Efficacy and Safety of Ibrutinib in Patients With Chronic Lymphocytic Leukemia and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers	Unknown status	NCT02991638	Phase 3	Ibrutinib
16	Study of Bendamustine Hydrochloride Injection in Previously Untreated Chronic Lymphocytic Leukemia Patients	Unknown status	NCT01657955	Phase 3	Bendamustine Hydrochloride Injection;Chlorambucil
17	Low Dose Chlorambucil Maintenance Vs. No Treatment Following High-Dose Chlorambucil Induction In Patients With Advanced B-Chronic Lymphocytic Leukemia. A Randomized Phase III Study Of The EORTC LG (CLL-3)	Unknown status	NCT00017108	Phase 3	chlorambucil;cyclophosphamide;fludarabine phosphate
18	Clinical Study of Chemoimmunotherapy With Fresh Frozen Plasma, High Dose Methylprednisolone and Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia	Unknown status	NCT01670812	Phase 3	FFP+HDMP+Rituximab
19	A Multi-centre Phase III Study to Evaluate Pre-emptive Tenofovir for Prevention of Hepatitis B Virus Reactivation in HBsAg Negative/Anti-HBc Positive Individuals Undergoing Anti-CD20-based Chemotherapy for Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia	Unknown status	NCT02186574	Phase 3	Tenofovir disoproxil;Placebo Oral Tablet
20	A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination With Chlorambucil, Acalabrutinib (ACP-196) in Combination With Obinutuzumab, and Acalabrutinib Monotherapy in Subjects With Previously Untreated CLL	Unknown status	NCT02475681	Phase 3	Acalabrutinib;Obinutuzumab;Chlorambucil
21	Phase III Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab (FCR) Versus Bendamustine and Rituximab (BR) in Patients With Previously Untreated Chronic Lymphocytic Leukaemia	Completed	NCT00769522	Phase 3	Bendamustine;Cyclophosphamide;Fludarabine
22	Phase III Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab (FCR) Versus Chemotherapy With Fludarabine and Cyclophosphamide (FC) Alone in Patients With Previously Untreated Chronic Lymphocytic Leukaemia	Completed	NCT00281918	Phase 3	Rituximab;Cyclophosphamide;Fludarabine Phosphate
23	An Open Label, Multicenter Study Investigating the Safety and Efficacy of Ofatumumab Therapy Versus Physicians' Choice in Patients With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukaemia (CLL)	Completed	NCT01313689	Phase 3	Ofatumumab;Physicians' Choice
24	A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial	Completed	NCT01231412	Phase 3	Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
25	INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation	Completed	NCT00799461	Phase 3
26	A Randomized, Multicenter, Open-Label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 (Ibrutinib) Versus Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Completed	NCT01973387	Phase 3	Rituximab;Ibrutinib
27	Single-agent Rituximab as Maintenance Treatment Versus Observation After Combined Induction Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab in Patients Older Than 65 Years With Previously Untreated Chronic Lymphocytic Leukemia: a Phase III Trial of FILO	Completed	NCT00645606	Phase 3
28	Open-Label, Single Arm, Phase 3b, Multi-Center Study Evaluating the Efficacy of Venetoclax (ABT 199) in Relapsed/Refractory Subjects With Chronic Lymphocytic Leukemia (CLL)	Completed	NCT02756611	Phase 3	Venetoclax
29	A Phase III, Open Label, Randomized Trial of Ofatumumab Added to Fludarabine-Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in Subjects With Relapsed Chronic Lymphocytic Leukemia	Completed	NCT00824265	Phase 3	OFC Infusion;FC infusion
30	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Lenalidomide (Revlimid®) as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia Following Second-Line Therapy (The Continuum Trial)	Completed	NCT00774345	Phase 3	Lenalidomide;Placebo
31	A Randomized Phase III Trial to Determine Whether Conjugated Pneumococcal Vaccine Can Improve the Immune Responsiveness Compared to Polyclonal Pneumococcal Vaccine in Patients With Untreated Chronic Lymphocytic Leukemia	Completed	NCT01892618	Phase 3	Prevenar 13;Pneumovax
32	A Study of IPI-145 and Ofatumumab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Previously Enrolled in Study IPI-145-07	Completed	NCT02049515	Phase 3	IPI-145 (duvelisib);Ofatumumab
33	A Randomized, Multi-center, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Completed	NCT02264574	Phase 3	Ibrutinib;Obinutuzumab;Chlorambucil
34	A Randomized, Open Label Study to Assess the Effect of Maintenance Treatment With Mabthera (Rituximab) Versus No Treatment, After Induction Treatment With Rituximab, Cladribine and Cyclophosphamide (RCC) on Progression-Free Survival in Previously Untreated Patients With Progressive B-Cell Chronic Lymphocytic Leukemia	Completed	NCT00718549	Phase 3	Cladribine;Cyclophosphamide;Rituximab
35	A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (DUO)	Completed	NCT02004522	Phase 3	Duvelisib;Ofatumumab
36	A Multicenter, Open-Label, Single-Arm, Phase IIIb, International Study Evaluating the Safety of Obinutuzumab Alone or in Combination With Chemotherapy in Patients With Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia	Completed	NCT01905943	Phase 3	Bendamustine;Chlorambucil;Cyclophosphamide;Fludarabine;Obinutuzumab
37	A Multicenter, Phase III, Open-Label, Randomized Study in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia to Evaluate the Benefit of Venetoclax (GDC-0199/ABT-199) Plus Rituximab Compared With Bendamustine Plus Rituximab	Completed	NCT02005471	Phase 3	Bendamustine;Venetoclax;Rituximab
38	Open-Label, Single Arm, Phase 3b, Multi-Center Study Evaluating the Impact of Venetoclax on the Quality of Life of Relapsed/Refractory Subjects With Chronic Lymphocytic Leukemia (CLL)	Completed	NCT02980731	Phase 3	Venetoclax
39	A Phase 3, Randomized, Study to Assess the Efficacy and Safety of Ublituximab in Combination With Ibrutinib Compared to Ibrutinib Alone, in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)	Completed	NCT02301156	Phase 3	Ublituximab;Ibrutinib
40	A Prospective Case Series of Subcutaneous Immunoglobulin for Prophylaxis of Infections in Patients With Chronic Lymphocytic Leukemia With Impaired Humoral Immunity	Completed	NCT03730129	Phase 2, Phase 3	Hizentra
41	Fludarabine Versus Chlorambucil in First Line Therapy of Elderly Patients (More Than 65 Years) With Advanced Chronic Lymphocytic Leukemia	Completed	NCT00262795	Phase 3	Fludarabine;Chlorambucil
42	Darbepoetin Alfa in Patients With Chronic Lymphocytic Leukemia and Comorbidity	Completed	NCT00281892	Phase 3	Fludarabine mono
43	Prognostic Factors and Risk-Adapted Therapy in Patients With Early Stage Chronic Lymphocytic Leukemia	Completed	NCT00262782	Phase 3	Fludarabine
44	A Prospective, Randomized, Open Label, Phase III Trial of Fludarabine, Cyclophosphamide, and Rituximab vs. Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-cell Chronic Lymphocytic Leukemia	Completed	NCT00254163	Phase 3	Fludarabine;Cyclophosphamide;Rituximab;Pentostatin
45	Fludarabine Versus Fludarabine Plus Cyclophosphamide in First Line Therapy of Younger Patients (Up to 65 Years) With Advanced Chronic Lymphocytic Leukemia (CLL)	Completed	NCT00276848	Phase 3	Fludarabine plus Cyclophosphamide;Fludarabine
46	Randomized Study Of Fludarabine And Cyclophosphamide With Or Without Genasense (Bcl-2 Antisense Oligonucleotide) In Subjects With Relapsed Or Refractory Chronic Lymphocytic Leukemia	Completed	NCT00024440	Phase 3	cyclophosphamide;fludarabine phosphate
47	Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Completed	NCT01611090	Phase 3	Ibrutinib;Bendamustine hydrochloride;Rituximab;Placebo
48	Phase III Randomized Trial of Fludarabine and Cyclophosphamide Versus Fludarabine for Previously Untreated Chronic Lymphocytic Leukemia	Completed	NCT00003764	Phase 3	cyclophosphamide;fludarabine phosphate
49	International, Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation Alone in Patients With Chronic Lymphocytic Leukemia	Completed	NCT01118234	Phase 3	Rituximab
50	A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia	Completed	NCT00046683	Phase 3	alemtuzumab

Search NIH Clinical Center for Leukemia, Chronic Lymphocytic 2

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

alemtuzumab

Chlorambucil

Cladribine

Cyclophosphamide

etoposide phosphate

fludarabine

Fludarabine phosphate

Ibrutinib

Ifosfamide

Immunoglobulins, Intravenous

mercaptopurine

pegaspargase

Uracil Mustard

Sources

Genetic Tests for Leukemia, Chronic Lymphocytic 2

Genetic tests related to Leukemia, Chronic Lymphocytic 2:

#	Genetic test	Affiliating Genes
1	Leukemia, Chronic Lymphocytic, Susceptibility to, 2 ²⁸

Sources

Anatomical Context for Leukemia, Chronic Lymphocytic 2

Organs/tissues related to Leukemia, Chronic Lymphocytic 2:

MalaCards : T Cells, Bone Marrow, B Cells, Myeloid, Lymph Node, Nk Cells, Bone

Sources

Publications for Leukemia, Chronic Lymphocytic 2

Articles related to Leukemia, Chronic Lymphocytic 2:

(show top 50) (show all 4752)

#	Title	Authors	PMID	Year
1	Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. ⁵⁷	Fabbri M...Croce CM	21205967	2011
2	Cloning and gene mapping of the chromosome 13q14 region deleted in chronic lymphocytic leukemia. ⁵⁷	Kalachikov S...Fischer SG	9205107	1997
3	Evidence for a new tumour suppressor locus (DBM) in human B-cell neoplasia telomeric to the retinoblastoma gene. ⁵⁷	Brown AG...Weir-Thompson EM	8490658	1993
4	The Bcl-2 family as a rational target for the treatment of B-cell chronic lymphocytic leukaemia. ⁵³ ⁶²	Capitani N...Baldari CT	20156175	2010
5	Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression. ⁵³ ⁶²	Ding W...Kay NE	19751240	2009
6	ZAP-70 and Syk expression in canine lymphoid cells and preliminary results on leukaemia cases. ⁵³ ⁶²	Mortarino M...Comazzi S	19144411	2009
7	TRAIL receptors in the serum of patients with B-cell chronic lymphocytic leukemia. ⁵³ ⁶²	Jablonska E...Sawicka-Powierza J	18190241	2008
8	ZAP-70 and CD38 expression are independent prognostic factors in patients with B-cell chronic lymphocytic leukaemia and combined analysis improves their predictive value. ⁵³ ⁶²	Hus I...Rolinski J	18519230	2008
9	What do somatic hypermutation and class switch recombination teach us about chronic lymphocytic leukaemia pathogenesis? ⁵³ ⁶²	Oppezzo P...Dighiero G	16323428	2005
10	[Some genomic aberrations in B-cell chronic lymphocytic leukemia and their clinical relevance. Part I. B-cell lymphocytic leukemia with TP53 gene deletion]. ⁵³ ⁶²	Koczkodaj D...Bojarska-Junak A	15052934	2003
11	Interferon-alpha, Bcl-2 expression and apoptosis in B-cell chronic lymphocytic leukemia. ⁵³ ⁶²	Jewell AP	8907268	1996
12	Alterations of multiple tumor suppressor genes (p53 (17p13), p16INK4 (9p21), and DBM (13q14)) in B-cell chronic lymphocytic leukemia. ⁵³ ⁶²	Newcomb EW...Lee SY	7576105	1995
13	Memory B-cell like chronic lymphocytic leukaemia is associated with specific methylation profile of WNT5A promoter and undetectable expression of WNT5A gene. ⁶²	Poppova L...Pospisilova S	35333703	2022
14	Chronic lymphocytic leukaemia/small lymphocytic lymphoma and mantle cell lymphoma: from early lesions to transformation. ⁶²	Sander B...Hsi ED	36454275	2022
15	Necrotizing herpes simplex lymphadenitis in a patient with chronic lymphocytic leukaemia/small lymphocytic lymphoma, clinically masquerading as Richter transformation. ⁶²	Carlsen ED...Aggarwal N	35811089	2022
16	Lymphomas associated with Epstein-Barr virus infection in 2020: Results from a large, unselected case series in France. ⁶²	Donzel M...de Martel C	36204003	2022
17	Obinutuzumab as consolidation after chemo-immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial. ⁶²	Munir T...Hillmen P	36017875	2022
18	Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis. ⁶²	Saleem K...Lontos K	36354020	2022
19	Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study. ⁶²	Shadman M...Sharman JP	36400069	2022
20	SOHO State of the Art Updates and Next Questions \| Mechanisms of Resistance to BCL2 Inhibitor Therapy in Chronic Lymphocytic Leukemia and Potential Future Therapeutic Directions. ⁶²	Bennett R...Tam C	35970756	2022
21	Low CD49d expression in newly diagnosed chronic lymphocytic leukaemia may be associated with high-risk features and reduced treatment-free-intervals. ⁶²	Elizabeth S...Carmel W	35776688	2022
22	Clinicopathological characteristics of individuals with coexisting melanoma and chronic lymphocytic leukaemia: a multicentre cohort study. ⁶²	Fisher RM...Matin RN	35801421	2022
23	Is unmeasurable residual disease (uMRD) the best surrogate endpoint for clinical trials, regulatory approvals and therapy decisions in chronic lymphocytic leukaemia (CLL)? ⁶²	Yang S...Gale RP	36100641	2022
24	ATM serine/threonine kinase germline mutations in chronic lymphocytic leukaemia come in different flavours. ⁶²	Rio-Machin A	36111522	2022
25	Cardiac toxicity in a pilot study of duvelisib and ibrutinib combination therapy for chronic lymphocytic leukaemia. ⁶²	Paul SR...Sun C	36366824	2022
26	Prognostic markers in patients with chronic lymphocytic leukaemia on targeted therapy, chemoimmunotherapy with anti-CD20 monoclonal antibody: a systematic review and meta-analysis of prognostic factors. ⁶²	Mkhwanazi ZA...Nkambule BB	36434612	2022
27	Front-line fludarabine-cyclophosphamide-rituximab (FCR) in 110 patients with chronic lymphocytic leukaemia (CLL): real-life experience with long-term outcomes, toxicities and responses to second-line therapies. ⁶²	Oliveira AC...Gonzalez-Barca E	36449134	2022
28	Rare germline ATM variants of uncertain significance in chronic lymphocytic leukaemia and other cancers. ⁶²	Petrackova A...Kriegova E	36029002	2022
29	Clonally related composite chronic lymphocytic leukaemia and mantle cell lymphoma. ⁶²	Dong Q...Zhao C	36375473	2022
30	Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial. ⁶²	Cramer P...Hallek M	35988545	2022
31	The evolving multi-agent options for chronic lymphocytic leukaemia treatment. ⁶²	de la Serna J...Baumann T	35988548	2022
32	Venetoclax activity in a patient with central nervous system involvement by chronic lymphocytic leukaemia. ⁶²	Soumerai JD...Ferry JA	36174642	2022
33	Cytomegalovirus DNAemia and disease: current-era epidemiology, clinical characteristics and outcomes in cancer patients other than allogeneic haemopoietic transplantation. ⁶²	Tay KH...Yong MK	34448333	2022
34	Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia. ⁶²	Hampel PJ...Parikh SA	35841338	2022
35	Acute myeloid leukaemia following direct acting antiviral drugs in HCV-infected patients: A 10 years' retrospective single-center study. ⁶²	Scheifer C...Lebray P	35933093	2022
36	Bioavailability of acalabrutinib suspension delivered via nasogastric tube in the presence or absence of a proton pump inhibitor in healthy subjects. ⁶²	Sharma S...Tomkinson H	35466438	2022
37	Improving outcomes for patients with lymphoma: design and development of the Australian and New Zealand Lymphoma and Related Diseases Registry. ⁶²	Lymphoma and Related Diseases Registry Investigators	36217114	2022
38	Resolution of melanoma to PD-1 blockade but simultaneous rapid progression of concomitant chronic lymphocytic leukemia. ⁶²	Burgess M...Gandhi MK	36273464	2022
39	Fibrillary and immunotactoid glomerulopathies in the Hunter region: a retrospective cohort study. ⁶²	Cohen AWS...Vilayur E	36305476	2022
40	No increased risk of mature B-cell non-Hodgkin lymphoma after Q fever detected: results from a 16-year ecological analysis of the Dutch population incorporating the 2007-2010 Q fever outbreak. ⁶²	Weehuizen JM...Oosterheert JJ	35352121	2022
41	A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma. ⁶²	Strati P...Budde LE	35861370	2022
42	Radiation and leukaemia: Which leukaemias and what doses? ⁶²	Gale RP	36220737	2022
43	Blood-stained tears-a red flag for malignancy? ⁶²	Kaushik M...Timlin H	36088421	2022
44	Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect. ⁶²	Wang H...Zhou K	36138486	2022
45	Clonally unrelated Richter syndrome are truly de novo diffuse large B-cell lymphomas with a mutational profile reminiscent of clonally related Richter syndrome. ⁶²	Favini C...Moia R	35829664	2022
46	Sex-specific familial aggregation of cancers in Finland. ⁶²	Sipila LJ...Pitkaniemi J	36068325	2022
47	Expression of BCL11A in chronic lymphocytic leukaemia. ⁶²	Tosic N...Karan-Djurasevic T	36120992	2022
48	Integrative epigenomics in chronic lymphocytic leukaemia: Biological insights and clinical applications. ⁶²	Kulis M...Martin-Subero JI	36121003	2022
49	Ibrutinib use, treatment duration, and concomitant medications in Australian patients with relapsed or refractory chronic lymphocytic leukaemia. ⁶²	Mulligan SP...Tam CS	35702012	2022
50	Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma. ⁶²	Nakhoda S...Wang YL	36029036	2022

Sources

Genes for Leukemia, Chronic Lymphocytic 2

Genes related to Leukemia, Chronic Lymphocytic 2 (1 elite genes):

(show all 11)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	CLLS2	Disrupted In B-Cell Neoplasia	Genetic Locus	50	Genetic linkage ⁵⁷ Susceptibility factor ⁵⁷
2	ZAP70	Zeta Chain Of T Cell Receptor Associated Protein Kinase 70	Protein Coding	10.87	Novoseek inferred ⁵³	18223290 15759031 17476690 (more) 16906587 16906577 16332969 17051526 19847197 18314442 19145677 15800671 19459926 19534392 15329427 19298722 16906582 17701587 17344921 16938520 14723013 16906581 17786276 16601244 18519230 15487457 16871389 20135127 19144411 18322442 17703441 17485110 16906579
3	CD38	CD38 Molecule	Protein Coding	10.7	Novoseek inferred ⁵³	15759031 16208411 19240243 (more) 12673718 10505750 18314442 15613544 17344921 19298722 17786276 16332969 8289967 18519230 15453928 17701587 15590397 12854897 18322442 17485110 16825496
4	CD5	CD5 Molecule	Protein Coding	9.57	Novoseek inferred ⁵³	7513207 1694698 8042591 (more) 1694132 18497318 10740408 9894463
5	FCER2	Fc Epsilon Receptor II	Protein Coding	9.28	Novoseek inferred ⁵³	10052715 15621797 7517747 (more) 1717071 8080994 19050243 8093369 11920207 7950920
6	MCL1	MCL1 Apoptosis Regulator, BCL2 Family Member	Protein Coding	9.27	Novoseek inferred ⁵³	19487028 14695629 19581935 (more) 15291360 15728130 19092849
7	IGHM	Immunoglobulin Heavy Constant Mu	Protein Coding	9.18	Novoseek inferred ⁵³	15325098 15820941 1282064
8	BCL3	BCL3 Transcription Coactivator	Protein Coding	9.18	Novoseek inferred ⁵³	8336935 8011990 11713278 (more) 16533741
9	MS4A1	Membrane Spanning 4-Domains A1	Protein Coding	9.11	Novoseek inferred ⁵³	1694698 11719378 18794139 (more) 18497318
10	BCL2	BCL2 Apoptosis Regulator	Protein Coding	8.82	Novoseek inferred ⁵³	8104532 9373241 17132110 (more) 8260892 8870373 15278764 16020508 8417785 8649796 9949631 18046447 8204892 8172820 9459175 15291360 8907268 10784395 12176904 18234901 11683718 9720722 7919349 12604404 20156175 7923926 16531274 8374905
11	ATM	ATM Serine/Threonine Kinase	Protein Coding	8.58	Novoseek inferred ⁵³	11468183 9892178 9788599 (more) 10738255 12149228 11875779 17875758 16938579 10681729 17350468 17213020 14607769 15692065 10397742

Sources

Variations for Leukemia, Chronic Lymphocytic 2

Sources

Expression for Leukemia, Chronic Lymphocytic 2

Search GEO for disease gene expression data for Leukemia, Chronic Lymphocytic 2.

Sources

Pathways for Leukemia, Chronic Lymphocytic 2

Pathways related to Leukemia, Chronic Lymphocytic 2 according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Hematopoietic Stem Cells and Lineage-specific Markers ⁶⁵	11.5	MS4A1 CD5 CD38
2	Interleukin-4 and Interleukin-13 signaling ⁶⁶	11.37	MCL1 FCER2 BCL2
3	Integrated cancer pathway ⁷⁴	11.06	BCL2 ATM
4	Inflammatory response pathway ⁷⁴	10.98	ZAP70 IGHM
5	Gemtuzumab ozogamicin Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰	10.79	BCL2 ATM
6	Regulation of apoptosis by parathyroid hormone-related protein ⁷⁴	10.75	MCL1 BCL2
7	TP53 network ⁷⁴ Show member pathways Activation, translocation and oligomerization of BAX ⁶⁶	10.67	BCL2 ATM
8	Hematopoietic stem cell gene regulation by GABP alpha/beta complex ⁷⁴	10.62	BCL2 ATM
9	IL-7 Signaling and its Primary Biological Effects in Different Immune Cell Types ⁶⁵ Show member pathways B-Cell Development ⁶⁴	9.86	MCL1 BCL2
10	MicroRNA network associated with chronic lymphocytic leukemia ⁷⁴	9.4	ZAP70 BCL2

Sources

GO Terms for Leukemia, Chronic Lymphocytic 2

Biological processes related to Leukemia, Chronic Lymphocytic 2 according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	regulation of apoptotic process	GO:0042981	9.8	MCL1 BCL3 BCL2 ATM
2	negative regulation of anoikis	GO:2000811	9.76	MCL1 BCL2
3	oocyte development	GO:0048599	9.73	BCL2 ATM
4	intrinsic apoptotic signaling pathway in response to DNA damage	GO:0008630	9.73	ATM BCL2 MCL1
5	negative regulation of T cell apoptotic process	GO:0070233	9.71	BCL3 BCL2
6	T cell apoptotic process	GO:0070231	9.67	BCL3 BCL2
7	response to cytokine	GO:0034097	9.55	MCL1 CD38 BCL2
8	B cell proliferation	GO:0042100	9.43	MS4A1 CD38 BCL2
9	B cell receptor signaling pathway	GO:0050853	9.23	MS4A1 IGHM CD38 BCL2